Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.44 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6234524 | 0.81 | LMNA (0.53) | TDP1MAPK1HPGDKMT2ALMNA | |
| SCHEMBL11213440 | 0.80 | HSD11B1 (0.57) | RECQLTDP1MAPK1KMT2AMAPT | |
| SCHEMBL6660239 | 0.79 | RECQL (0.53) | RECQLTDP1MAPK1HPGDKMT2A | |
| SCHEMBL17417729 | 0.78 | KMT2A (0.52) | TDP1MAPK1HPGDKMT2AMAPT | |
| SCHEMBL6664422 | 0.78 | KMT2A (0.52) | RECQLTDP1MAPK1HPGDKMT2A | |
| SCHEMBL6659940 | 0.76 | RECQL (0.50) | RECQLTDP1MAPK1HPGDKMT2A | |
| SCHEMBL28310222 | 0.76 | LMNA (0.53) | TDP1MAPK1HPGDKMT2ALMNA | |
| SCHEMBL1315543 | 0.76 | LMNA (0.58) | TDP1MAPK1KMT2AMAPTLMNA | |
| SCHEMBL1516246 | 0.76 | MAPK1 (0.58) | RECQLTDP1MAPK1HPGDKMT2A | |
| SCHEMBL6660055 | 0.75 | RECQL (0.49) | RECQLTDP1MAPK1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101356165-A | Process for preparing gemcitabine and related intermediates | CHEMAGIS LTD (IL) | 2009-01-28 | — | — | CN | disclosed |
| WO-2008129530-A1 | GEMCITABINE PRODUCTION PROCESS | CHEMAGIS LTD. (IL) | 2008-10-30 | — | — | WO | disclosed |
| US-20080262215-A1 | GEMCITABINE PRODUCTION PROCESS | CHEMAGIS LTD. (IL) | 2008-10-23 | — | — | US | disclosed |
| WO-2007070804-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-06-21 | — | — | WO | disclosed |
| EP-0732338-B1 | 2,2-Difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides | LILLY CO ELI (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-0732338-A1 | 2,2-Difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides | ELI LILLY AND COMPANY (US) | 1996-09-18 | — | — | EP | disclosed |
| US-5521294-A | 2,2-difluoro-3-carbamoyl ribose sulfonate compounds and process for the preparation of beta nucleosides | ELI LILLY AND COMPANY (US) | 1996-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262215-A1 | GEMCITABINE PRODUCTION PROCESS | SAMHD1, DCK, DCTD | RECQL 3675/4885TDP1 2174/4885MAPK1 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.